Sorriso Pharmaceuticals

Developing novel oral antibodies for immune-mediated disease

Sandy, United States · Founded 2020 · $31.0M raised

Headquarters
Sandy, Utah
Employees
1–10
Founded
2020
Business Model
B2C
Total Funding
$31.0M
Last Round
$31.0M Series ADec 2021
Rounds
1

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

Indexed holds 1 funding round and 2 investors for this company. The full record is or through the API.

About

Sorriso Pharmaceuticals is a biopharmaceutical company advancing a pipeline of disease-modifying antibodies for the treatment of immune-mediated diseases, including Crohn's disease and ulcerative colitis. The company's proprietary oral delivery platform generates potent antibodies that can be administered orally and are designed to maintain therapeutic activity throughout the human intestine. Its lead candidate, SOR102, simultaneously inhibits TNF-alpha and IL-23(p19), two clinically validated drivers of inflammatory bowel disease (IBD). In December 2024, Sorriso announced positive Phase 1b clinical trial results for SOR102 in ulcerative colitis, with data subsequently published in Lancet Gastroenterology & Hepatology and presented at ECCO 2025.

Summary

Sorriso Pharmaceuticals is a Biotech company based in Sandy, United States, founded in 2020. It has raised $31.0M in total across 1 round, most recently a $31.0M Series A round in Dec 2021. Investors include New Enterprise Associates and Arix Bioscience.

Tech & App Stack

2 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series ASeries ADec 2021
$31.0M

Investors

Similar Companies

Abogen Biosciences

Abogen Biosciences develops RNA therapeutics using integrated mRNA design, lipid nanoparticle del...

Suzhou, China201–500Biotech, Drug Discovery
Extension RoundTotal funding$1.2BNov 2021
Mirador Therapeutics

Clinical-stage precision medicine company developing targeted therapies for immune-mediated infla...

San Diego, United States11–50Biotech, Drug Discovery
Series BTotal funding$650.0MOct 2025
OricIPO

San Diego-based clinical stage biopharmaceutical company focused on the development of small mole...

South San Francisco, United States51–200Biotech, Healthcare
Private EquityTotal funding$647.0MFeb 2026
Neumora TherapeuticsIPO

Clinical-stage biopharmaceutical developing precision medicines targeting novel mechanisms to tre...

Watertown, United States51–200Biotech, Drug Discovery
Series BTotal funding$612.0MOct 2022
AsymchemIPO

Asymchem is a pharmaceutical CDMO providing R&D, chemistry, manufacturing, and control services t...

Tianjin, China5001–10000Biotech, Drug Discovery
Private EquityTotal funding$2.3BFeb 2020
Paratek PharmaceuticalsAcquired

Paratek Pharmaceuticals develops and delivers innovative treatments for serious infectious diseas...

Boston, United States201–500Biotech, Healthcare
ConvertibleTotal funding$1.8BApr 2018

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Sorriso Pharmaceuticals on Indexed.vc
<a href="https://indexed.vc/companies/sorriso-pharmaceuticals"><img src="https://indexed.vc/api/badge/company/sorriso-pharmaceuticals" alt="Sorriso Pharmaceuticals on Indexed.vc" width="260" height="76" /></a>